Literature DB >> 2857007

Immunogenicity of recombinant yeast hepatitis B vaccine.

M Davidson, S Krugman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2857007     DOI： 10.1016/s0140-6736(85)92000-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.

Authors:  E Dahl-Hansen; J C Siebke; S S Frøland; M Degré
Journal:  Epidemiol Infect       Date:  1990-02       Impact factor: 2.451

2.  Antibody responses to recombinant and plasma derived hepatitis B vaccines.

Authors:  S E Brown; C Stanley; C R Howard; A J Zuckerman; M W Steward
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

3.  Four-year experience with a recombinant hepatitis B vaccine.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

Review 4.  Immunoprophylaxis of hepatitis B in India.

Authors:  Y K Joshi
Journal:  Indian J Pediatr       Date:  1988 Sep-Oct       Impact factor: 1.967

5.  A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees.

Authors:  Y Itoh; E Takai; H Ohnuma; K Kitajima; F Tsuda; A Machida; S Mishiro; T Nakamura; Y Miyakawa; M Mayumi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

6.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

7.  Yeast recombinant hepatitis B vaccine.

Authors:  M R Hilleman
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

8.  Translation products of pre-S(1), pre-S(2) regions and the S gene of hepatitis B virus: susceptibility of their antigenic activities to treatment with heat, urea, formalin or pepsin.

Authors:  H Ohnuma; A Machida; E Takai; F Tsuda; H Miyamoto; T Tanaka; K Oda; S Usuda; T Nakamura; Y Miyakawa
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.